Incyte Corporation

INCYintermediary

Incyte is a specialty biopharmaceutical company focused on oncology and inflammation, anchored by the blockbuster JAK inhibitor Jakafi and expanding into dermatology with Opzelura.

⇄ Compare

Products & Revenue

Product Revenue Share

Revenue Breakdown ($3.9B)

Static data (loading live financials…)

Jakafi (55%)

Opzelura (18%)

Other Products (12%)

Royalties & Milestones (15%)

Segment Breakdown & Key Customers

Product Details

Jakafi (ruxolitinib)55%

First-in-class JAK1/JAK2 inhibitor for myelofibrosis and GVHD

Opzelura (ruxolitinib cream)18%

Topical JAK inhibitor for atopic dermatitis and vitiligo

Monjuvi (tafasitamab)8%

Anti-CD19 antibody for diffuse large B-cell lymphoma

Royalties & Pipeline19%

Royalties from Pemazyre, Zynyz, and pipeline collaboration payments

Supply Chain Relationships

Competitors

Eli Lilly and Company

JAK inhibitor market (Olumiant)

Impact: Medium — competing JAK inhibitors

AbbVie Inc.

JAK inhibitor market (Rinvoq)

Impact: High — Rinvoq is major JAK competitor

Key Customers

Walgreens Boots Alliance

Specialty pharmacy distribution

Impact: Medium — pharmacy channel

Macro & Market Context

제약 / 바이오Sector News

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Upcoming Catalysts

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Latest News

Loading news...

AI Analysis

Click "Get AI Analysis" for an AI-powered supply chain analysis of Incyte Corporation.

Company Info

Headquarters

Wilmington, Delaware, USA

Founded

1991

Employees

2,300+

Website

incyte.com

Sector Overview — 제약 / 바이오

Sector News